Tapewire

Nasdaq · USD

COGT

Cogent Biosciences, Inc.

Export transactions ↓
Tapewire entity
3793
SEC CIK
0001622229
Parsed reports
248

Last 12 months

Inside the activity.

0 purchase rows · 8 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202504
Jan 202601
Feb 202600
Mar 202601
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202602
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
October 01, 2026 Filed Oct 5, 2026 20:30 UTC GrantStock Option (Right to Buy) · Derivative 759 $0.00 Strike: $31.59 $0.00
Disclosure

SEC source: 0001193125-26-414218 · ownership.xml · derivative · entry 1

Ferrante Karen Jean · CIK 0001598502 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 759

Underlying: Common Stock · 759 shares

Expires 2036-10-01

F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

Read SEC document
August 27, 2026 Filed Aug 31, 2026 21:01 UTC Exercise / conversionStock Option (Right to Buy) · Derivative 3,583 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0001193125-26-377001 · ownership.xml · derivative · entry 6

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,583 shares

Expires 2030-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.

F4 · derivative.exercise_date: These options are fully vested.

Read SEC document
August 27, 2026 Filed Aug 31, 2026 21:01 UTC Exercise / conversionStock Option (Right to Buy) · Derivative 41,927 $0.00 Strike: $5.64 $0.00
Disclosure

SEC source: 0001193125-26-377001 · ownership.xml · derivative · entry 5

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,773

Underlying: Common Stock · 41,927 shares

Expires 2035-06-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.

F4 · derivative.exercise_date: These options are fully vested.

Read SEC document
August 27, 2026 Filed Aug 31, 2026 21:01 UTC SaleCommon Stock 3,161 $37.54 $118,662.68
Disclosure

SEC source: 0001193125-26-377001 · ownership.xml · nonDerivative · entry 4

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $37.46 to $37.65. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
August 27, 2026 Filed Aug 31, 2026 21:01 UTC SaleCommon Stock 42,349 $37.09 $1,570,830.28
Disclosure

SEC source: 0001193125-26-377001 · ownership.xml · nonDerivative · entry 3

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,161

F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $36.46 to $37.45. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
August 27, 2026 Filed Aug 31, 2026 21:01 UTC Exercise / conversionCommon Stock 3,583 $2.52 $9,029.16
Disclosure

SEC source: 0001193125-26-377001 · ownership.xml · nonDerivative · entry 2

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,510

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.

Read SEC document
August 27, 2026 Filed Aug 31, 2026 21:01 UTC Exercise / conversionCommon Stock 41,927 $5.64 $236,468.28
Disclosure

SEC source: 0001193125-26-377001 · ownership.xml · nonDerivative · entry 1

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,927

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.

Read SEC document
July 01, 2026 Filed Jul 6, 2026 20:30 UTC GrantStock Option (Right to Buy) · Derivative 627 $0.00 Strike: $38.48 $0.00
Disclosure

SEC source: 0001193125-26-296249 · ownership.xml · derivative · entry 1

Ferrante Karen Jean · CIK 0001598502 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 627

Underlying: Common Stock · 627 shares

Expires 2036-07-01

F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:30 UTC GrantStock Option (Right to Buy) · Derivative 17,901 $0.00 Strike: $31.98 $0.00
Disclosure

SEC source: 0001193125-26-267662 · ownership.xml · derivative · entry 1

CAIN CHRISTOPHER W. · CIK 0001817733 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,901

Underlying: Common Stock · 17,901 shares

Expires 2036-06-09

F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

F2 · ownership.direct: Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:30 UTC
Ros MatthewDirector
GrantStock Option (Right to Buy) · Derivative 17,901 $0.00 Strike: $31.98 $0.00
Disclosure

SEC source: 0001193125-26-267666 · ownership.xml · derivative · entry 1

Ros Matthew · CIK 0001673802 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,901

Underlying: Common Stock · 17,901 shares

Expires 2036-06-09

F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:30 UTC GrantStock Option (Right to Buy) · Derivative 17,901 $0.00 Strike: $31.98 $0.00
Disclosure

SEC source: 0001193125-26-267667 · ownership.xml · derivative · entry 1

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,901

Underlying: Common Stock · 17,901 shares

Expires 2036-06-09

F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:30 UTC GrantStock Option (Right to Buy) · Derivative 17,901 $0.00 Strike: $31.98 $0.00
Disclosure

SEC source: 0001193125-26-267663 · ownership.xml · derivative · entry 1

Ferrante Karen Jean · CIK 0001598502 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,901

Underlying: Common Stock · 17,901 shares

Expires 2036-06-09

F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:30 UTC GrantStock Option (Right to Buy) · Derivative 17,901 $0.00 Strike: $31.98 $0.00
Disclosure

SEC source: 0001193125-26-267665 · ownership.xml · derivative · entry 1

Harwin Peter Evan · CIK 0001663607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,901

Underlying: Common Stock · 17,901 shares

Expires 2036-06-09

F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

F2 · ownership.direct: Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:30 UTC
Shegog ToddDirector
GrantStock Option (Right to Buy) · Derivative 17,901 $0.00 Strike: $31.98 $0.00
Disclosure

SEC source: 0001193125-26-267670 · ownership.xml · derivative · entry 1

Shegog Todd · CIK 0001714564 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,901

Underlying: Common Stock · 17,901 shares

Expires 2036-06-09

F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

Read SEC document
May 19, 2026 Filed May 21, 2026 20:30 UTC
Robbins Andrew RDirector · President and CEO
GiftCommon Stock 160,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-234578 · ownership.xml · nonDerivative · entry 2

Robbins Andrew R · CIK 0001590157 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By trust

Disclosed balance after: 160,000

F1 · kind: On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes.

Read SEC document
May 19, 2026 Filed May 21, 2026 20:30 UTC
Robbins Andrew RDirector · President and CEO
GiftCommon Stock 160,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-234578 · ownership.xml · nonDerivative · entry 1

Robbins Andrew R · CIK 0001590157 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 497,503

F1 · kind: On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes.

Read SEC document
April 01, 2026 Filed Apr 3, 2026 20:01 UTC GrantStock Option (Right to Buy) · Derivative 686 $0.00 Strike: $35.24 $0.00
Disclosure

SEC source: 0001193125-26-142082 · ownership.xml · derivative · entry 1

Ferrante Karen Jean · CIK 0001598502 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 686

Underlying: Common Stock · 686 shares

Expires 2036-04-01

F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

Read SEC document
March 31, 2026 Filed Apr 1, 2026 01:30 UTC ConversionSeries A Convertible Preferred Stock · Derivative 28,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-26-038057 · tm2610819-2_4seq1.xml · derivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 39,414

Underlying: Common Stock · 7,000,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 250 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On March 31, 2026, the Reporting Persons converted 28,000 shares of Series A Convertible Preferred Stock into 7,000,000 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series A Convertible Preferred Stock.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 250 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On March 31, 2026, the Reporting Persons converted 28,000 shares of Series A Convertible Preferred Stock into 7,000,000 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series A Convertible Preferred Stock.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 250 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On March 31, 2026, the Reporting Persons converted 28,000 shares of Series A Convertible Preferred Stock into 7,000,000 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series A Convertible Preferred Stock.

F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
March 31, 2026 Filed Apr 1, 2026 01:30 UTC SaleCommon Stock 7,000,000 $34.66 $242,620,000.00
Disclosure

SEC source: 0001104659-26-038057 · tm2610819-2_4seq1.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 5,503,418

F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
March 31, 2026 Filed Apr 1, 2026 01:30 UTC ConversionCommon Stock 7,000,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-26-038057 · tm2610819-2_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 12,503,418

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 250 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On March 31, 2026, the Reporting Persons converted 28,000 shares of Series A Convertible Preferred Stock into 7,000,000 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series A Convertible Preferred Stock.

F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
January 22, 2026 Filed Jan 23, 2026 01:09 UTC SaleCommon Stock 3,500,000 $36.40 $127,400,000.00
Disclosure

SEC source: 0001104659-26-005924 · tm263873-2_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 5,503,418

F1 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
January 01, 2026 Filed Jan 5, 2026 21:01 UTC GrantStock Option (Right to Buy) · Derivative 643 $0.00 Strike: $34.74 $0.00
Disclosure

SEC source: 0001193125-26-002367 · ownership.xml · derivative · entry 1

Ferrante Karen Jean · CIK 0001598502 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 643

Underlying: Common Stock · 643 shares

Expires 2036-01-01

F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

Read SEC document
December 26, 2025 Filed Dec 30, 2025 16:01 UTC
Kearns EvanChief Legal Officer
SaleCommon Stock 65,000 $38.70 $2,515,500.00
Disclosure

SEC source: 0001193125-25-337052 · ownership.xml · nonDerivative · entry 1

Kearns Evan · CIK 0001745285 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,398

F1 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.52 to $38.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · balance_after: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 26, 2025 Filed Dec 30, 2025 21:01 UTC
Green John L.Chief Financial Officer
SaleCommon Stock 77,000 $38.68 $2,978,360.00
Disclosure

SEC source: 0001193125-25-337051 · ownership.xml · nonDerivative · entry 1

Green John L. · CIK 0001709773 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,834

F1 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.51 to $38.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · balance_after: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 26, 2025 Filed Dec 30, 2025 21:01 UTC
Sachs JessicaChief Medical Officer
SaleCommon Stock 82,642 $38.70 $3,198,245.40
Disclosure

SEC source: 0001193125-25-337050 · ownership.xml · nonDerivative · entry 1

Sachs Jessica · CIK 0001782545 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,938

F1 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.53 to $38.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · balance_after: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 26, 2025 Filed Dec 30, 2025 21:01 UTC
Robinson John EdwardChief Scientific Officer
SaleCommon Stock 90,000 $38.74 $3,486,600.00
Disclosure

SEC source: 0001193125-25-337049 · ownership.xml · nonDerivative · entry 1

Robinson John Edward · CIK 0001856514 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,002

F1 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.51 to $39.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · balance_after: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 16:01 UTC
Pinnow ColeChief Commercial Officer
GrantStock Option (Right to Buy) · Derivative 65,000 $0.00 Strike: $39.45 $0.00
Disclosure

SEC source: 0001193125-25-326774 · ownership.xml · derivative · entry 4

Pinnow Cole · CIK 0002024135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2035-12-17

F6 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 16:01 UTC
Pinnow ColeChief Commercial Officer
Tax withholdingCommon Stock 94,800 $39.45 $3,739,860.00
Disclosure

SEC source: 0001193125-25-326774 · ownership.xml · nonDerivative · entry 3

Pinnow Cole · CIK 0002024135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,650

F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.

F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 16:01 UTC
Pinnow ColeChief Commercial Officer
GrantCommon Stock 214,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326774 · ownership.xml · nonDerivative · entry 2

Pinnow Cole · CIK 0002024135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 311,450

F3 · shares: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs").

Read SEC document
December 17, 2025 Filed Dec 19, 2025 16:01 UTC
Pinnow ColeChief Commercial Officer
GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326774 · ownership.xml · nonDerivative · entry 1

Pinnow Cole · CIK 0002024135 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,450

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.

F2 · balance_after: Includes an aggregate of 1,602 shares of common stock acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan on June 30, 2025.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 16:01 UTC
Kearns EvanChief Legal Officer
GrantStock Option (Right to Buy) · Derivative 55,000 $0.00 Strike: $39.45 $0.00
Disclosure

SEC source: 0001193125-25-326772 · ownership.xml · derivative · entry 4

Kearns Evan · CIK 0001745285 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-12-17

F5 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 16:01 UTC
Kearns EvanChief Legal Officer
Tax withholdingCommon Stock 125,602 $39.45 $4,954,998.90
Disclosure

SEC source: 0001193125-25-326772 · ownership.xml · nonDerivative · entry 3

Kearns Evan · CIK 0001745285 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,398

F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.

F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 16:01 UTC
Kearns EvanChief Legal Officer
GrantCommon Stock 260,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326772 · ownership.xml · nonDerivative · entry 2

Kearns Evan · CIK 0001745285 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

F2 · shares: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs").

Read SEC document
December 17, 2025 Filed Dec 19, 2025 16:01 UTC
Kearns EvanChief Legal Officer
GrantCommon Stock 40,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326772 · ownership.xml · nonDerivative · entry 1

Kearns Evan · CIK 0001745285 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Robbins Andrew RDirector · President and CEO
GrantStock Option (Right to Buy) · Derivative 245,000 $0.00 Strike: $39.45 $0.00
Disclosure

SEC source: 0001193125-25-326775 · ownership.xml · derivative · entry 4

Robbins Andrew R · CIK 0001590157 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 245,000

Underlying: Common Stock · 245,000 shares

Expires 2035-12-17

F5 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Robbins Andrew RDirector · President and CEO
Tax withholdingCommon Stock 367,497 $39.45 $14,497,756.65
Disclosure

SEC source: 0001193125-25-326775 · ownership.xml · nonDerivative · entry 3

Robbins Andrew R · CIK 0001590157 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 657,503

F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.

F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Robbins Andrew RDirector · President and CEO
GrantCommon Stock 840,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326775 · ownership.xml · nonDerivative · entry 2

Robbins Andrew R · CIK 0001590157 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,025,000

F2 · shares: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs").

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Robbins Andrew RDirector · President and CEO
GrantCommon Stock 185,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326775 · ownership.xml · nonDerivative · entry 1

Robbins Andrew R · CIK 0001590157 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,000

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Robinson John EdwardChief Scientific Officer
GrantStock Option (Right to Buy) · Derivative 65,000 $0.00 Strike: $39.45 $0.00
Disclosure

SEC source: 0001193125-25-326776 · ownership.xml · derivative · entry 4

Robinson John Edward · CIK 0001856514 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2035-12-17

F5 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Robinson John EdwardChief Scientific Officer
Tax withholdingCommon Stock 139,998 $39.45 $5,522,921.10
Disclosure

SEC source: 0001193125-25-326776 · ownership.xml · nonDerivative · entry 3

Robinson John Edward · CIK 0001856514 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 230,002

F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.

F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Robinson John EdwardChief Scientific Officer
GrantCommon Stock 320,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326776 · ownership.xml · nonDerivative · entry 2

Robinson John Edward · CIK 0001856514 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 370,000

F2 · shares: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs").

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Robinson John EdwardChief Scientific Officer
GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326776 · ownership.xml · nonDerivative · entry 1

Robinson John Edward · CIK 0001856514 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Sachs JessicaChief Medical Officer
GrantStock Option (Right to Buy) · Derivative 65,000 $0.00 Strike: $39.45 $0.00
Disclosure

SEC source: 0001193125-25-326773 · ownership.xml · derivative · entry 4

Sachs Jessica · CIK 0001782545 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2035-12-17

F5 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Sachs JessicaChief Medical Officer
Tax withholdingCommon Stock 154,716 $39.45 $6,103,546.20
Disclosure

SEC source: 0001193125-25-326773 · ownership.xml · nonDerivative · entry 3

Sachs Jessica · CIK 0001782545 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,580

F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.

F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Sachs JessicaChief Medical Officer
GrantCommon Stock 320,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326773 · ownership.xml · nonDerivative · entry 2

Sachs Jessica · CIK 0001782545 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,296

F2 · shares: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs").

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Sachs JessicaChief Medical Officer
GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326773 · ownership.xml · nonDerivative · entry 1

Sachs Jessica · CIK 0001782545 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,296

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Green John L.Chief Financial Officer
GrantStock Option (Right to Buy) · Derivative 65,000 $0.00 Strike: $39.45 $0.00
Disclosure

SEC source: 0001193125-25-326771 · ownership.xml · derivative · entry 4

Green John L. · CIK 0001709773 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2035-12-17

F5 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Green John L.Chief Financial Officer
Tax withholdingCommon Stock 145,007 $39.45 $5,720,526.15
Disclosure

SEC source: 0001193125-25-326771 · ownership.xml · nonDerivative · entry 3

Green John L. · CIK 0001709773 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,834

F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.

F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Green John L.Chief Financial Officer
GrantCommon Stock 300,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326771 · ownership.xml · nonDerivative · entry 2

Green John L. · CIK 0001709773 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 353,841

F2 · shares: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs").

Read SEC document
December 17, 2025 Filed Dec 19, 2025 21:01 UTC
Green John L.Chief Financial Officer
GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-326771 · ownership.xml · nonDerivative · entry 1

Green John L. · CIK 0001709773 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,841

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.